
Ongoing Trials Aim to Remove Carboplatin from TCHP and Reduce Treatment Cycles in HER2+ Breast Cancer
Within the past decade, the HER2-positive breast cancer landscape has demonstrated significant improvements. However, coming off the heels of the 2025 ASCO Annual Meeting, data from the phase 2 CompassHER2 pCR trial (NCT04266249) and the phase 3 neoCARHP …